Outcomes of Venetoclax‐Based Regimens Versus Intensive and Reduced‐Intensity Chemotherapy in Newly Diagnosed AML
Outcomes von Venetoclax-basierten Regimen im Vergleich zu intensiver und reduzierte-intensiver Chemotherapie bei neu diagnostizierter AML
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72475 ↗Auf einen Blick
In einer multizentrischen retrospektiven Studie bei 1.370 Patient:innen mit neu diagnostizierter AML zeigte Venetoclax eine höhere Ansprechrate als reduzierte-intensivierte Chemotherapie. Bei älteren Patient:innen war auch die Frühsterblichkeit niedriger.
Fragestellung
Wie schneiden Venetoclax-basierte Regime im Vergleich zu intensiver oder reduzierte-intensiver Chemotherapie bei neu diagnostizierter AML ab?
Methode
Multizentrische retrospektive Studie mit 1.370 Patient:innen; Vergleich von intensiver Chemotherapie, reduzierte-intensiver Chemotherapie und Venetoclax, auch bei Patient:innen ab 60 Jahren.
Ergebnisse
Im Gesamtkollektiv war die ORR mit VEN ähnlich wie bei IC und höher als bei rIC (74,3 % vs. 60,2 %; p = 0,034). Bei Älteren: höhere ORR als rIC (75,7 % vs. 50,5 %; p = 0,001), niedrigere 60-Tage-Frühsterblichkeit (1,4 % vs. 20,0 %; p < 0,001) und längeres medianes EFS (9,6 vs. 6,6 Monate; p = 0,031).
Einschränkungen
Die Baseline-Charakteristika unterschieden sich deutlich zwischen den Behandlungsgruppen; Überlebensanalysen wurden als unterstützend und explorativ gewertet.
Schlussfolgerung der Autor:innen
Die höhere Ansprechrate und die niedrigere frühe Mortalität unter VEN waren die konsistentesten Befunde; die vergleichenden Überlebensdaten waren unterstützend, aber explorativ.
Kernaussagen
- VEN hatte im Gesamtkollektiv eine höhere ORR als rIC
- Bei Älteren war die 60-Tage-Frühsterblichkeit unter VEN niedriger
- Survival-Befunde waren nicht eindeutig und explorativ
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 11.11.2026. Verfasst von Jiadan Sheng und 54 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute, Sulfonamides, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Leukemia Research Fund.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Venetoclax‐based regimens (VEN) have been widely adopted as frontline therapeutic options for elderly patients with acute myeloid leukemia (AML). However, comprehensive real‐world comparisons of VEN with conventional intensive or reduced‐intensity chemotherapy remain limited.
Methods
In this multicenter retrospective study, we evaluated treatment patterns and outcomes in 1370 patients with newly diagnosed AML. Patients were classified into three cohorts according to their frontline treatment: intensive chemotherapy (IC), reduced‐intensity chemotherapy (rIC), or VEN. Analyses were performed in both the overall cohort and elderly patients (aged ≥ 60 years), including baseline comparisons, uni‐ and multivariable analyses, and subgroup analyses.
Results
Baseline characteristics differed substantially among treatment cohorts; patients treated with VEN were older and had a higher prevalence of adverse‐risk disease than those receiving IC or rIC . In the overall cohort, VEN achieved an overall response rate ( ORR ) comparable to IC and higher than rIC (74.3% vs. 60.2%, p = 0.034). Among elderly patients, VEN was associated with a higher ORR than rIC (75.7% vs. 50.5%, p = 0.001), and the favorable ORR findings remained significant after correction for multiple testing. VEN was also associated with a lower 60‐day early‐death rate than rIC in elderly patients (1.4% vs. 20.0%, p < 0.001), suggesting better early treatment tolerability. Median event‐free survival was longer with VEN than with rIC in the primary elderly cohort analysis (9.6 vs. 6.6 months, p = 0.031), and this difference persisted in a sensitivity analysis censoring at allogeneic hematopoietic stem cell transplantation, although it was attenuated in landmark and propensity‐score‐based sensitivity analyses. Overall survival did not differ significantly between the two cohorts (15.9 vs. 11.0 months, p = 0.102).
Conclusion
The higher response rate and lower early mortality with VEN were the most consistent findings, whereas comparative survival outcomes were considered supportive but exploratory.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nippon Medical School, Tokyo, Japan.
- Hemato-Oncology Department, St. Luke's International Hospital, Tokyo, Japan.
- Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
- Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
- Department of Hematology, Institute of Science Tokyo, Tokyo, Japan.
- Division of Hematology, Meiwa Hospital, Nishinomiya, Hyogo, Japan.
ORCID-Profile: Jiadan Sheng, Yasunobu Nagata, Atsushi Marumo, Satoshi Wakita, Masuho Saburi, Keisuke Tanaka, Takehiko Mori, Kunio Hayashi, Hideaki Nitta, Kensuke Usuki, Taku Tsukamoto, Junya Kuroda, Kenjiro Mitsuhashi, Keiichi Moriya, Shohei Mizuno, Sayuri Motomura, Tomonori Nakazato, Shinya Kimura, Shinichi Kako, Akiko Hashimoto, Junya Kanda, Masao Ogata, Eriko Sato, Noriko Doki, Eri Kawata, Haruko Tashiro, Atsushi Satake, Daichi Nishiyama, Katsuhiro Shono, Yoshinobu Kanda, Hiroki Yamaguchi
Förderung
- Japan Society for the Promotion of Science
- Japan Leukemia Research Fund
Zitieren
APA
Sheng, J., Nagata, Y., Marumo, A., Sakaguchi, M., Arai, K., Kitano, T., Wakita, S., Mori, S., Masuda, S., Saburi, M., Tanaka, K., Mori, T., Hayashi, K., Nitta, H., Usuki, K., Maeda, T., Hara, S., Tsukamoto, T., Kuroda, J., …, & Yamaguchi, H. (2026). Outcomes of Venetoclax‐Based Regimens Versus Intensive and Reduced‐Intensity Chemotherapy in Newly Diagnosed AML. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72475
Vancouver
Sheng J, Nagata Y, Marumo A, Sakaguchi M, Arai K, Kitano T, et al. Outcomes of Venetoclax‐Based Regimens Versus Intensive and Reduced‐Intensity Chemotherapy in Newly Diagnosed AML. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72475
BibTeX
@article{Sheng2026,
author = {Sheng, Jiadan and Nagata, Yasunobu and Marumo, Atsushi and Sakaguchi, Masahiro and Arai, Kunihito and Kitano, Tomoaki and Wakita, Satoshi and Mori, Shinichiro and Masuda, Shinichi and Saburi, Masuho and Tanaka, Keisuke and Mori, Takehiko and Hayashi, Kunio and Nitta, Hideaki and Usuki, Kensuke and Maeda, Tetsuo and Hara, Satoru and Tsukamoto, Taku and Kuroda, Junya and Takayama, Nobuyuki and Nakayama, Kazutaka and Mitsuhashi, Kenjiro and Moriya, Keiichi and Mizuno, Shohei and Motomura, Sayuri and Nakazato, Tomonori and Ando, Jun and Ueki, Toshimitsu and Okamoto, Sho and Kimura, Shinya and Uchiyama, Hitoji and Kako, Shinichi and Hagihara, Masao and Hashimoto, Akiko and Minakata, Daisuke and Fukunaga, Keiko and Kanda, Junya and Takano, Kuniko and Ogata, Masao and Sato, Eriko and Sekiguchi, Yasunobu and Doki, Noriko and Kamitsuji, Yuri and Kawata, Eri and Tashiro, Haruko and Edahiro, Taro and Ichinohe, Tatsuo and Nagao, Yuhei and Takada, Satoru and Satake, Atsushi and Nishiyama, Daichi and Uoshima, Nobuhiko and Shono, Katsuhiro and Kanda, Yoshinobu and Yamaguchi, Hiroki},
title = {Outcomes of Venetoclax‐Based Regimens Versus Intensive and Reduced‐Intensity Chemotherapy in Newly Diagnosed AML},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72475}
}
EUVIMED